Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke

NCT01849887 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study was never started

Conditions

Ischemic Stroke

Interventions

BIOLOGICAL: bone marrow-derived mesenchymal stem cells
DRUG: Placebo

Sponsor

University of California, Irvine